Jingsong Yang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jingsong Yang has a total of 44 co-authors. Here are the top co-authors by number of shared publications:
Robert A. Copeland
Oncology Research and Development, GlaxoSmithKline, 1250 South Collegeville Road, Collegeville, PA 19426, USA
3 shared publicationsZhihong Lai
Oncology Research and Development, GlaxoSmithKline, 1250 South Collegeville Road, Collegeville, PA 19426, USA
3 shared publicationsPeter J. Tummino
Enzymology & Mechanistic Pharmacology, GlaxoSmithKline, 1250 South Collegeville Road, Collegeville, PA 19426, U.S.A.
2 shared publicationsAllen Oliff
Platform Technology and Science, GlaxoSmithKline, 1250 South Collegeville Road, Collegeville, PA 19426, USA
1 shared publicationBrett Siegfried
Platform Technology and Science, GlaxoSmithKline, 1250 South Collegeville Road, Collegeville, PA 19426, USA
1 shared publicationConnie Erickson-Miller
Oncology Research and Development, GlaxoSmithKline, 1250 South Collegeville Road, Collegeville, PA 19426, USA
1 shared publication
Latest Publications
- 1 February 2011
- Published by Elsevier in Chemistry & Biology
- Vol. 18 (2) , 177-186
Discovery and Characterization of a Cell-Permeable, Small-Molecule c-Abl Kinase Activator that Binds to the Myristoyl Binding Site
- 1 February 2011
- Published by Elsevier in Chemistry & Biology
- Vol. 18 (2) , 177-186
Discovery and Characterization of a Cell-Permeable, Small-Molecule c-Abl Kinase Activator that Binds to the Myristoyl Binding Site
- 13 May 2009
- Published by Portland Press Ltd. in Biochemical Journal
- Vol. 420 (2) , 259-265
Biochemical characterization of GSK1070916, a potent and selective inhibitor of Aurora B and Aurora C kinases with an extremely long residence time1
The Aurora kinases AurA, B and C are serine/threonine protein kinases that play essential roles in mitosis and cytokinesis. Among them, AurB is required for maintaining proper chromosome alignment, separation and segregation during mitosis, and regulating a number of critical processes involved in cytokinesis. AurB overexpression has been observed in a variety of cancer cell lines, and inhibition of AurB has been shown to induce tumour regression in mouse xenograft models. In the present study we report the enzymatic characterization of a potent and selective AurB/AurC inhibitor. GSK1070916 is a reversible and ATP-competitive inhibitor of the AurB–INCENP (inner centromere protein) enzyme. It selectively inhibits AurB–INCENP (Ki*=0.38±0.29 nM) and AurC–INCENP (Ki*=1.5±0.4 nM) over AurA–TPX2 (target protein for Xenopus kinesin-like protein 2) (Ki=490±60 nM). Inhibition of AurB–INCENP and AurC–INCENP is time-dependent, with an enzyme-inhibitor dissociation half-life of >480 min and 270±28 min respectively. The extremely slow rate of dissociation from the AurB and AurC enzymes distinguishes GSK1070916 from two other Aurora inhibitors in the clinic, AZD1152 and VX-680 (also known as MK-0457).
- 13 May 2009
- Published by Portland Press Ltd. in Biochemical Journal
- Vol. 420 (2) , 259-265
Biochemical characterization of GSK1070916, a potent and selective inhibitor of Aurora B and Aurora C kinases with an extremely long residence time1
The Aurora kinases AurA, B and C are serine/threonine protein kinases that play essential roles in mitosis and cytokinesis. Among them, AurB is required for maintaining proper chromosome alignment, separation and segregation during mitosis, and regulating a number of critical processes involved in cytokinesis. AurB overexpression has been observed in a variety of cancer cell lines, and inhibition of AurB has been shown to induce tumour regression in mouse xenograft models. In the present study we report the enzymatic characterization of a potent and selective AurB/AurC inhibitor. GSK1070916 is a reversible and ATP-competitive inhibitor of the AurB–INCENP (inner centromere protein) enzyme. It selectively inhibits AurB–INCENP (Ki*=0.38±0.29 nM) and AurC–INCENP (Ki*=1.5±0.4 nM) over AurA–TPX2 (target protein for Xenopus kinesin-like protein 2) (Ki=490±60 nM). Inhibition of AurB–INCENP and AurC–INCENP is time-dependent, with an enzyme-inhibitor dissociation half-life of >480 min and 270±28 min respectively. The extremely slow rate of dissociation from the AurB and AurC enzymes distinguishes GSK1070916 from two other Aurora inhibitors in the clinic, AZD1152 and VX-680 (also known as MK-0457).
- Open Access
- 1 February 2009
- Published by Elsevier in SLAS Discovery
- Vol. 14 (2) , 111-120
Defining Balanced Conditions for Inhibitor Screening Assays That Target Bisubstrate Enzymes
- 1 February 2009
- Published by Elsevier in SLAS Discovery
- Vol. 14 (2) , 111-120
Open AccessDefining Balanced Conditions for Inhibitor Screening Assays That Target Bisubstrate Enzymes
- 12 December 2008
- Published by Portland Press Ltd. in Biochemical Journal
- Vol. 417 (1) , 355-360
The catalytic role of INCENP in Aurora B activation and the kinetic mechanism of Aurora B/INCENP
Aurora kinases are a family of serine/threonine protein kinases that play essential roles in mitosis and cytokinesis. AurB (Aurora B kinase) has shown a clear link to cancer and is being pursued as an attractive cancer target. Multiple small molecules targeting AurB have entered the clinic for the treatment of cancer. A protein cofactor, INCENP (inner centromere protein), regulates the cellular localization and activation of AurB. In the present study, we examined the effect of INCENP on the activation kinetics of AurB and also elucidated the kinetic mechanism of AurB-catalysed substrate phosphorylation. We have concluded that: (i) substoichoimetric concentrations of INCENP are sufficient for AurB autophosphorylation at the activation loop residue Thr232, and hence INCENP plays a catalytic role in AurB autophosphorylation; (ii) AurB/INCENP-catalysed phosphorylation of a peptide substrate proceeds through a rapid equilibrium random Bi Bi kinetic mechanism; and (iii) INCENP has relatively minor effects on the specific activity of AurB using a peptide substrate when compared with its role in AurB autoactivation. These results indicate that the effects of INCENP, and probably accessory proteins in general, may differ when enzymes are acting on different downstream targets.
- 12 December 2008
- Published by Portland Press Ltd. in Biochemical Journal
- Vol. 417 (1) , 355-360
The catalytic role of INCENP in Aurora B activation and the kinetic mechanism of Aurora B/INCENP
Aurora kinases are a family of serine/threonine protein kinases that play essential roles in mitosis and cytokinesis. AurB (Aurora B kinase) has shown a clear link to cancer and is being pursued as an attractive cancer target. Multiple small molecules targeting AurB have entered the clinic for the treatment of cancer. A protein cofactor, INCENP (inner centromere protein), regulates the cellular localization and activation of AurB. In the present study, we examined the effect of INCENP on the activation kinetics of AurB and also elucidated the kinetic mechanism of AurB-catalysed substrate phosphorylation. We have concluded that: (i) substoichoimetric concentrations of INCENP are sufficient for AurB autophosphorylation at the activation loop residue Thr232, and hence INCENP plays a catalytic role in AurB autophosphorylation; (ii) AurB/INCENP-catalysed phosphorylation of a peptide substrate proceeds through a rapid equilibrium random Bi Bi kinetic mechanism; and (iii) INCENP has relatively minor effects on the specific activity of AurB using a peptide substrate when compared with its role in AurB autoactivation. These results indicate that the effects of INCENP, and probably accessory proteins in general, may differ when enzymes are acting on different downstream targets.